CTOs on the Move

Neumora Therapeutics

www.neumoratx.com

 
Brain diseases collectively represent one of the greatest challenges of our generation, affecting upwards of 1.5 billion people. However, treatments for many of the most prevalent brain disorders have been dominated by a single class of drugs, such as serotonin targeting antidepressants for MDD, leaving patients with a high degree of unmet medical need given the lack of diverse treatment options and mechanisms of action. We are taking a fundamentally different approach to the way treatments for brain diseases are developed. Our pipeline is comprised of programs pursuing therapeutically relevant targets implicated in Central Nervous System (CNS) diseases, each targeting ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.neumoratx.com
  • 490 Arsenal Way Suite 200
    Watertown, MA USA 02472
  • Phone: 857.760.0900

Executives

Name Title Contact Details

Similar Companies

TransDermal Technologies Inc

TransDermal Technologies Inc is a North Palm Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Theranos

Our mission is to make actionable information accessible to everyone at the time it matters. By making actionable information accessible to everyone in the world at the time it matters most, we are working to facilitate the early detection and prevention of disease, and empower people everywhere to live their best possible lives.

Memphis Bio Works

Memphis Bio Works is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CPort Solutions

CPort Solutions is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Moderna Therapeutics

Moderna is a clinical stage pioneer of messenger RNA Therapeutics™, an entirely new in vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of diseases and conditions. Moderna is developing and plans to commercialize its innovative mRNA drugs through its own ventures and its strategic relationships with established pharmaceutical and biotech companies. Its current ventures are: Onkaido, focused on oncology, Valera, focused on infectious diseases, Elpidera, focused on rare diseases, and Caperna, focused on personalized cancer vaccines. Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca, Alexion Pharmaceuticals and Merck.